In a groundbreaking study published in the highly respected hematology journal Blood, researchers from the University of Guelph have unveiled a novel vulnerability in acute myeloid leukemia (AML) cells that could revolutionize therapeutic approaches to this aggressive blood cancer. Led by Dr. Paul Spagnuolo from the Department of Food Science, the team discovered that AML cells exhibit a critical dependency on a unique metabolic pathway involving peroxisomal fatty acid oxidation. This pathway is facilitated by the protein ABCD1, which serves as a molecular gatekeeper, allowing the processing of very specific fatty acids essential for leukemia cell survival. The insights gained open up intriguing new possibilities for targeted cancer treatment.
Cells require energy to sustain their functions, and most healthy cells demonstrate remarkable metabolic flexibility, capable of switching between energy sources such as glucose, fats, or amino acids depending on availability. However, the team led by Dr. Spagnuolo found that AML cells have a distinct metabolic inflexibility. Unlike their healthy counterparts, leukemia cells are essentially metabolically “locked in,” relying almost exclusively on the breakdown of certain long-chain fatty acids using peroxisomal pathways. This reliance effectively becomes a metabolic Achilles’ heel that researchers believe can be exploited to selectively eliminate cancer cells.
Central to this metabolic dependency is the protein ABCD1, embedded in the membrane of cellular organelles called peroxisomes. ABCD1 functions as a critical transporter, importing specific fatty acids into peroxisomes where they undergo beta-oxidation—a process vital for converting fats into usable cellular energy. The new research reveals that AML cells overexpress ABCD1 to an extraordinary degree compared to normal blood cells, enabling a heightened fatty acid metabolism that sustains their unchecked growth and survival.
In a remarkable twist, the University of Guelph team has developed a compound derived from jojoba—a desert plant renowned for its oils widely used in cosmetics—that effectively inhibits ABCD1 function. This novel inhibitor halts the cellular import of fatty acids into peroxisomes, rapidly causing toxic accumulation of fats within AML cells. Without the ability to switch metabolic gears or compensate for the block in fatty acid processing, leukemia cells undergo metabolic stress leading to programmed cell death, or apoptosis.
Unlike many anti-cancer agents that broadly affect both healthy and cancerous cells, this targeted approach demonstrates a striking specificity. Healthy cells exposed to the jojoba-derived compound readily compensate by activating alternate metabolic pathways, such as glycolysis, thus maintaining their energy balance and viability. This selective lethality offers substantial promise as a therapeutic window, potentially allowing for treatments that minimize collateral damage and adverse side effects commonly associated with conventional chemotherapy.
Dr. Spagnuolo emphasizes the importance of this discovery as a clear example of how plant-derived bioactive compounds can transcend their traditional uses and contribute to medicinal chemistry and oncology. While jojoba oil has long been a staple ingredient in skin and hair care for its moisturizing properties, isolating its components to inhibit a key metabolic protein in cancer cells marks a pioneering step in translational food science research.
This study is part of a broader research trajectory investigating the anti-cancer potential of nutraceuticals—biologically active compounds found in foods and plants—that may eventually be developed into pharmacologically optimized drugs. Past research from the same group explored compounds from avocados, which showed promise in delaying leukemia progression in preclinical models. The emerging picture suggests a growing palette of natural compounds with molecular targets that might be harnessed to disrupt cancer metabolism specifically.
Although these findings herald a new frontier in AML treatment, Dr. Spagnuolo tempers expectations by clarifying that this is not an endorsement of dietary changes or the idea that consuming jojoba products directly could cure leukemia. The current compound is still in early developmental stages and requires significant refinement to enhance its pharmacodynamics and safety profile before it could advance into clinical human trials.
The potential applications of ABCD1 inhibition extend beyond AML, as preliminary evidence indicates that other cancers may similarly depend on peroxisomal fatty acid oxidation for survival. This raises the tantalizing prospect that future therapeutics based on this mechanism might offer a broad-spectrum anti-cancer strategy, targeting the metabolic vulnerabilities across a variety of malignancies.
Metabolic reprogramming is an increasingly recognized hallmark of cancer, offering compelling new avenues for intervention. By focusing on the unique fuel dependencies of leukemia cells, this research not only enriches understanding of cancer cell biology but also exemplifies how interdisciplinary approaches—bridging food science, plant biochemistry, and oncology—can generate innovative solutions to longstanding clinical challenges.
The discovery of this jojoba-derived ABCD1 inhibitor brings renewed optimism to the search for more effective and less toxic leukemia therapies. As researchers continue to refine the molecule and explore its full potential, the intersection of natural compound chemistry and cancer metabolism stands poised to usher in a new era of precision oncology treatment options, delivering hope to patients worldwide.
Subject of Research: Cells
Article Title: Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells
News Publication Date: 11-Jun-2026
Web References: DOI Link
Image Credits: University of Guelph
Keywords: Acute myeloid leukemia, AML, ABCD1 protein, peroxisomal fatty acid oxidation, jojoba compound, metabolic vulnerability, targeted cancer therapy, plant-based nutraceuticals, cancer metabolism, leukemia treatment, cell metabolism, experimental study
Tags: ABCD1 protein role in leukemiaacute myeloid leukemia metabolic vulnerabilityexploiting metabolic pathways for cancer therapyfatty acid metabolism in cancer cellshematology journal Blood leukemia studyleukemia cell metabolic inflexibilitymetabolic Achilles’ heel in leukemianovel AML therapeutic approachesperoxisomal fatty acid oxidation in AMLplant-derived therapies for blood cancertargeted treatment for acute myeloid leukemiaUniversity of Guelph cancer research
